Theo Hodge, MD
Infectious Disease · Washington, DCNPI 1912007725
Payments from drug & device makers
Across 1,835 payments — averaging $1389.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1.5M
- Viiv Healthcare Company$654K
- AbbVie$323K
- Janssen Products, LP$52K
- Janssen Scientific Affairs, LLC$36K
- Theratechnologies Inc.$2K
- plus $4K from 21 others
Across 22 payments — averaging $113.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2K
- Viiv Healthcare Company$180
What the payments were for
- Consulting fees$170,68317%
- Speaking & faculty fees$700,04468%
- Travel & lodging$122,49312%
- Food & beverage$32,2023%
- Education$2610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 806 | $1,478,300 |
| Viiv Healthcare Company | 678 | $653,992 |
| AbbVie(2 entities) | 78 | $322,853 |
| Janssen Products, LP | 58 | $51,616 |
| Janssen Scientific Affairs, LLC | 38 | $35,855 |
| Theratechnologies Inc. | 27 | $2,449 |
| GSK | 11 | $1,215 |
| Johnson & Johnson | 45 | $958 |
| Merck | 23 | $365 |
| Napo Pharmaceuticals Inc | 16 | $282 |
| Novo Nordisk | 11 | $216 |
| Lilly USA, LLC | 10 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $134 |
| AstraZeneca | 5 | $97 |
| Arbor Pharmaceuticals, Inc. | 7 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Bayer | 2 | $47 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $27 |
| Amgen | 1 | $24 |
| Mylan Institutional Inc. | 1 | $23 |
| Shionogi Inc | 1 | $21 |
| Dermira, Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,548,940 in reported general payments places this provider in the 95th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 150 | $709,840 |
| DovatoDolutegravir Sodium/Lamivudine | 68 | $221,845 |
| PrezcobixDarunavir/Cobicistat | 36 | $129,266 |
| JulucaDolutegravir/Rilpivirine | 24 | $119,537 |
| DescovyEmtricitabine/Tenofov Alafenam | 38 | $117,536 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $105,617 |
| OzempicSemaglutide | 34 | $45,244 |
| TivicayDolutegravir Sodium | 15 | $38,516 |
| JardianceEmpagliflozin | 21 | $30,451 |
| Maraviroc | 22 | $28,983 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $24,632 |
| PifeltroDoravirine | 12 | $20,787 |
| FarxigaDapagliflozin Propanediol | 11 | $12,869 |
| Testosterone | 18 | $6,603 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,478,300 | $827,376188 claims |
| Viiv Healthcare CompanyDovato, Juluca, Cabenuva, Tivicay | $653,992 | $485,515121 claims |
| Johnson & JohnsonPrezcobix | $958 | $129,26636 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $27 | $55,08345 claims |
| Novo NordiskOzempic | $216 | $45,24434 claims |
| MerckPifeltro | $365 | $20,78712 claims |
| AstraZenecaFarxiga | $97 | $12,86911 claims |
| GSKBreo Ellipta | $1,215 | $5,72714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 infectious disease providers in District of Columbia.
Other infectious disease in Washington
- Princy KumarWashington$4.4M
- David DiemertWashington$2.3M
- Jesse GoodmanWashington$1.8M
- Jose BordonWashington$1.5M
- Robert GasserWashington$922K
- Marc SiegelWashington$801K
- Deborah GoldsteinWashington$707K
- Glenn WortmannWashington$604K
- Rebecca KumarWashington$497K
- Gary SimonWashington$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.